Medical News Summary: Comparison trial shows Fosamax to be a winner for osteoporosis treatment
About: Comparison trial shows Fosamax to be a winner for osteoporosis treatment
Date: 15 October 2004
Source: Onlypunjab
Medical News Summary (summary of medical news story as reported by Onlypunjab): A comparison trial concluded that Fosamax (alendronate sodium) was more effective at maintaining or increasing bone mass density than Actonel (risedronate). Fosamax is the only FDA approved treatment for osteporosis and aims to reduce the risk of fractures in postmenopausal women. However, the drugs both had side effects at a similar rate and included: abdominal pain, diarrhea, constipation, heartburn, flatulence, nausea, vomiting, joint pain, muscle pain and headache. Fosamax is not recommended for use by people suffering gastrointestinal problems.
URL: http://www.onlypunjab.com/real/fullstory-newsID-6280.html
Related Disease Topics: Osteoporosis
Related Symptom Topics: Decreased bone mass density, abdominal pain, diarrhea, constipation, heartburn, flatulence, nausea, vomiting, joint pain, muscle pain, headache
Related Medical News Channels: This medical news summary article refers to the following medical channel categories:
- Medication
- medication and osteoporosis
- medication and abdominal pain
- medication and diarrhea
- medication and constipation
- medication and heartburn
- medication and flatulence
- medication and nausea
- medication and joint pain
- medication and muscle pain
- medication and headache
Medical Tools & Articles:
Next articles:
Medical Articles: